Physician profile
Sofia Vaisman
NPI 1497846638
$13,281.92
in general payments reported to CMS, 2019-2025
59 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 94% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $1,660 · 2021: $2,570 · 2022: $2,262 · 2023: $1,847 · 2024: $1,416 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,280.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,840.71 | 2019-2025 | Linzess, Viberzi, Vraylar |
| Amgen INC. | $1,343.68 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $745.63 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $682.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $632.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.86 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $521.29 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $507.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $485.74 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $456.39 | 2019-2025 | Breztri, Airsupra |
| Amarin Pharma, INC. | $432.03 | 2019-2023 | |
| Lilly USA, LLC | $407.45 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $395.19 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $283.85 | 2022 | |
| Abbott Laboratories | $261.94 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Vaisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.